Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Precision Colchicine Intervention to Suppress Atherosclerosis in TET2 Clonal Hematopoiesis : a Pilot Clinical Trial (PRECISE)

NCT07362966 is registered in ClinicalTrials.gov with Shenyang Northern Hospital as lead sponsor.

NCT NCT07362966
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07362966 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Precision Colchicine Intervention to Suppress Atherosclerosis in TET2 Clonal Hematopoiesis : a Pilot Clinical Trial (PRECISE)
Lead sponsor
Shenyang Northern Hospital
Phase
Phase 4
Overall status
Recruiting
Start date
June 8, 2026
Completion date
December 1, 2027
Enrollment
120 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

clonal hematopoiesis of indeterminate potential, colchicine, coronary atherosclerosis management